HEALTHY EXTRACTS INC.

Overview

Compare with Target Group Inc., Functional Brands Inc. or PANACEA LIFE SCIENCES HOLDINGS, INC., or pick any stock.

• TickerHYEX on OTC¹
• IndustryMedicinal Chemicals & Botanical Products¹
• HeadquartersHenderson, Nevada¹
• Incorporated inNV³
• Business address7375 Commercial Way, Suite 125, Henderson, Nv 89011³
• Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Since our acquisitions of Bergamet and UBN, we have focused on increasing revenue, maintaining our margins, and generating positive cash flow from our existing operations. In part, at least with respect to Bergamet and UBN, we have been successful in meeting these objectives and our business has remained relatively unchanged. In October 2025, we acquired Gummy USA, which accelerated our revenue growth and increased our gross profit.⁴ From its latest annual report

Corporate structure

HEALTHY EXTRACTS INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What HEALTHY EXTRACTS INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Intangibles and goodwill

Inventory

Properties, in its own words

We do not currently own, lease or use any office space as we operate on a virtual basis. However, we lease warehouse facilities as follows:

Reference · Address · Description · Start Date · End Date · Amount

Item 2 of the 10-K filed Apr 9, 2026.⁴

Leadership

Who has led HEALTHY EXTRACTS INC., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerPatrick Stiles Oct 24, 2017 to Oct 24, 2017¹³
• Chief executive officerFred Covely Jan 19, 2016 to Oct 23, 2017¹⁴
• PresidentDonald William Swanson Aug 22, 2025 to now¹⁵
• PresidentSanjeevkumar Ratanshi Javia Feb 22, 2019 to Feb 22, 2019¹⁶
• PresidentKevin Pitts Oct 22, 2018 to Jul 8, 2022¹⁷
• PresidentJoseph Nejman Apr 28, 2017 to May 25, 2017¹⁸
• PresidentPatrick Stiles Oct 24, 2017 to Oct 24, 2017¹³
• PresidentFred Covely Jan 19, 2016 to Jan 19, 2016¹⁴
• Chief financial officerRobert Michael Madden Jul 5, 2022 to Jul 5, 2022¹⁹
• Chief financial officerWilliam C. Bossung Jan 25, 2016 to Oct 23, 2017²⁰

Former names

• HEALTHLY EXTRACTS INC.Mar 11, 2021 to Mar 11, 2021³
• GREY CLOAK TECH INC.Jan 12, 2015 to Feb 19, 2021³

Timeline

1. Sep 18, 20268-K Executive or director change²²
2. Jul 24, 20268-K Entered a material agreement; Unregistered sale of shares²³
3. Jul 13, 20268-K Executive or director change²⁴
4. Jul 6, 20268-K Executive or director change²⁵
5. May 18, 20268-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares²⁶
6. Oct 2, 20258-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale²⁷
7. Sep 23, 20258-K Executive or director change²⁸
8. Jul 24, 20258-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares²⁹
9. May 10, 20248-K Entered a material agreement; Change of auditor³⁰
10. Apr 24, 20248-K Ended a material agreement³¹
11. Dec 29, 20238-K Bylaws or fiscal year changed³²
12. Nov 8, 20238-K Entered a material agreement³³
13. Oct 24, 2017New chief executive Patrick Stiles becomes CEO¹³
14. Jan 19, 2016New chief executive Fred Covely becomes CEO¹⁴

Filings

70 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 21 major events, 7 insider forms, 1 large holders, 20 other. The latest 20:

1. Sep 18, 20268-K HEALTHY EXTRACTS INC. - FORM 8-K SEC FILING EDGAR
2. Aug 14, 202610-Q HEALTHY EXTRACTS INC. - FORM 10-Q SEC FILING EDGAR
3. Jul 24, 20268-K HEALTHY EXTRACTS INC. - FORM 8-K SEC FILING EDGAR
4. Jul 13, 20268-K HEALTHY EXTRACTS INC. - FORM 8-K SEC FILING EDGAR
5. Jul 6, 20268-K HEALTHY EXTRACTS INC. - FORM 8-K SEC FILING EDGAR
6. May 18, 20268-K HEALTHY EXTRACTS INC. - FORM 8-K SEC FILING EDGAR
7. May 14, 202610-Q HEALTHY EXTRACTS INC. - FORM 10-Q SEC FILING EDGAR
8. Apr 9, 202610-K HEALTHY EXTRACTS INC. - FORM 10-K SEC FILING EDGAR
9. Apr 1, 2026NT 10-K HEALTHY EXTRACTS INC. 12B-25 EDGAR
10. Nov 14, 202510-Q HEALTHY EXTRACTS INC. - FORM 10-Q SEC FILING EDGAR
11. Oct 2, 20258-K HEALTHY EXTRACTS INC. - FORM 8-K SEC FILING EDGAR
12. Sep 23, 20258-K HEALTHY EXTRACTS INC. - FORM 8-K SEC FILING EDGAR
13. Aug 22, 2025SCHEDULE 13D EDGAR
14. Aug 22, 20254 PRIMARY DOCUMENT EDGAR
15. Aug 22, 20253 PRIMARY DOCUMENT EDGAR
16. Aug 13, 202510-Q HEALTHY EXTRACTS INC. - FORM 10-Q SEC FILING EDGAR
17. Jul 24, 20258-K HEALTHY EXTRACTS INC. - FORM 8-K SEC FILING EDGAR
18. May 13, 202510-Q HEALTHY EXTRACTS INC. - FORM 10-Q SEC FILING EDGAR
19. Apr 22, 202510-K/A HEALTHY EXTRACTS INC. - FORM 10-K SEC FILING EDGAR
20. Apr 1, 202510-K HEALTHY EXTRACTS INC. - FORM 10-K SEC FILING EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Donald William SwansonSCHEDULE 13D, 1 filing Aug 22, 2025³⁴

SEC filer profile

How HEALTHY EXTRACTS INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARHEALTHY EXTRACTS INC.¹
• CIK0001630176
• Employer ID (EIN)47-2594704⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inNevada⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2833 Medicinal Chemicals & Botanical Products¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address7375 Commercial Way, Suite 125, Henderson, NV 89011¹
• Phone702-505-0471¹
• Shares outstanding14,741,348 as of Aug 14, 2026²
• Public float$4.1M as of ⁴
• AuditorBush & Associates CPA LLC, Las Vegas, Nevada PCAOB ID 6797⁴
• On EDGAR sinceJan 12, 2015¹
• Filings195 in all: 8-K (45), 10-Q (34), 10-K (11), 4 (11), S-1/A (11), UPLOAD (11), 3 (10), 1-A/A (7)¹
  All 30 form types

  NT 10-Q (7), NT 10-K (5), PRE 14C (5), CORRESP (4), DEF 14C (4), 10-Q/A (3), DEF 14A (3), PRE 14A (3), SC 13G (3), 10-K/A (2), D (2), EFFECT (2), S-1 (2), SC 13D (2), 1-A (1), 424B3 (1), 8-A12G (1), POS AM (1), QUALIF (1), RW (1), S-8 (1), SCHEDULE 13D (1)

• Latest filingsAnnual report (10-K) Apr 9, 2026
  Quarterly report (10-Q) Aug 14, 2026
  Proxy statement (DEF 14A) Feb 28, 2018
  Latest 8-K (8-K) Sep 18, 2026

Risk factors and legal proceedings

The risks HEALTHY EXTRACTS INC. names in Item 1A of its 10-K filed Apr 9, 2026: 41 risks under these headings, as written.⁴

• We rely on a single supplier relationship for licensing and manufacturing, and the termination of that agreement could have material effect on the cost of our products and the manufacturing of our finished goods.
• We are not profitable, and we do not expect to be profitable in the near future. There is no assurance our future operations will result in revenues sufficient to obtain or sustain profitability. If we cannot generate sufficient revenues to operate profitably, we may suspend or cease operations.
• Our success is linked to the size and growth rate of the vitamin, mineral and supplement market and an adverse change in the size or growth rate of that market could have a material adverse effect on us.
• We are highly dependent upon consumers’ perception of the safety and quality of our products and if we fail to maintain adequate quality standards for our products and services, or if our products become subject to regulatory investigations, our business may be adversely affected and our reputation harmed.
• Our success depends on our ability to maintain the value and reputation of our brands.
• We may fail to attract, acquire or retain customers at our current or anticipated future growth rate, or may fail to do so in a cost-effective manner, which would adversely affect our business, financial condition and results of operations.
• We rely on internet search engines, lead generators, and social networking sites to help drive traffic to our website and the sale of our products, and if we fail to appear prominently in the search results or fail to drive traffic through paid advertising, our traffic and product sales would decline and our business would be adversely affected.
• If we are unable to anticipate customer preferences and successfully develop new and innovative products in a timely manner or effectively manage the introduction of new or enhanced products, then our business may be adversely affected.
• If we are unable to sustain pricing levels for our products, our business could be adversely affected.
• We face intense competition from competitors that are larger, more established and that possess greater resources than we do, and if we are unable to compete effectively, we may be unable to gain sufficient market share to sustain profitability.
• Adverse economic conditions may harm our business.
• Overall tightening of the labor market, increases in labor costs or any possible labor unrest may adversely affect our business and results of operations.

Legal proceedings

None of our officers or directors has, in the past ten years, filed bankruptcy, been convicted in a criminal proceeding or named in a pending criminal proceeding, been the subject of any order, judgment, or decree of any court permanently or temporarily enjoining him or her from any securities activities, or any other disclosable event required by Item 401(f) of Regulation S-K.

On November 14, 2022, BergaMet NA, LLC, our subsidiary, received a warning letter from the FDA regarding claims we allegedly make about our Cholesterol Command product. Specifically, the warning letter related to claims on our website, Facebook page, and the webpage of a retailer claim that the products are intended for use in the cure, mitigation, treatment, or prevention of disease because they reduce cholesterol or are an anti-inflammatory. On December 1, 2022, we responded to the warning letter notifying the FDA that we had hired a third-party to review our advertising and revise portions of our website, Facebook page, and online product listings. This was the only warning letter we received from the FDA to date.

Other than as set forth above, we are not a party to or otherwise involved in any legal proceedings.

In the ordinary course of business, we are from time to time involved in various pending or threatened legal actions. The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon our financial condition and/or results of operations. However, in the opinion of our management, other than as set forth herein, matters currently pending or threatened against us are not expected to have a material adverse effect on our financial position or results of operations.

The opening of Item 3, Legal Proceedings.⁴